Akorn acquires minority stake in ophthalmic R&D firm Aciex
This article was originally published in Scrip
Executive Summary
Akorn, a US niche pharmaceutical firm, has agreed to acquire an undisclosed minority stake in Aciex Therapeutics, a ophthalmic drug development firm based in Westborough, Massachusetts with a pipeline comprising both clinical-stage and preclinical-stage candidates.